

James C Cloyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4123066/publications.pdf>

Version: 2024-02-01

63
papers

2,139
citations

304743

22
h-index

233421

45
g-index

63
all docs

63
docs citations

63
times ranked

2329
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 380, 104-113.	2.5	4
2	Estimating the National Population of Hospitalized Chronic Baclofen Users: A Cross-Sectional Analysis of a Commercial Claims Database. <i>Drugs - Real World Outcomes</i> , 2022, 9, 307-314.	1.6	2
3	Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 763-768.	2.0	3
4	Identifying Biological Signatures of N-Acetylcysteine for Non-Suicidal Self-Injury in Adolescents and Young Adults. <i>Journal of Psychiatry and Brain Science</i> , 2021, 6, .	0.5	1
5	Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. <i>Epilepsia</i> , 2021, 62, 795-806.	5.1	39
6	Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. <i>Epilepsia</i> , 2021, 62, 846-856.	5.1	30
7	Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus. <i>Neurology</i> , 2021, 96, e2372-e2386.	1.1	6
8	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson's Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. <i>Metabolites</i> , 2021, 11, 145.	2.9	11
9	A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. <i>Clinical and Translational Science</i> , 2021, 14, 1444-1451.	3.1	1
10	Population Pharmacokinetic Analysis of N-Acetylcysteine in Pediatric Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplant. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1638-1645.	2.0	3
11	Characterizing Baclofen Withdrawal: A National Survey of Physician Experience. <i>Pediatric Neurology</i> , 2021, 122, 106-109.	2.1	3
12	Translational and Clinical Pharmacology Considerations in Drug Repurposing for X-linked Adrenoleukodystrophy - A Rare Peroxisomal Disorder. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	2
13	N-Acetylcysteine Reverses the Mitochondrial Dysfunction Induced by Very Long-Chain Fatty Acids in Murine Oligodendrocyte Model of Adrenoleukodystrophy. <i>Biomedicines</i> , 2021, 9, 1826.	3.2	13
14	Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 564-573.	3.6	4
15	GBA1 mutations: Prospects for exosomal biomarkers in α -synuclein pathologies. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 35-46.	1.1	11
16	N-acetylcysteine Provides Cytoprotection in Murine Oligodendrocytes through Heme Oxygenase-1 Activity. <i>Biomedicines</i> , 2020, 8, 240.	3.2	10
17	4512 Allopregnanolone Dose Finding for Status Epilepticus Treatment by Pharmacokinetic-Pharmacodynamic Modeling using Quantitative EEG in Dogs. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 1-2.	0.6	1
18	The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. <i>Epilepsia</i> , 2020, 61, e66-e70.	5.1	8

#	ARTICLE	IF	CITATIONS
19	Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. <i>Lancet, The</i> , 2020, 395, 1217-1224.	13.7	143
20	Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 744-750.	2.0	25
21	Synergistic chaperone activity of N-acetylcysteine and its metabolite L-cysteine in Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2020, 129, S84.	1.1	3
22	Patients with Gaucher disease display systemic oxidative stress dependent on therapy status. <i>Molecular Genetics and Metabolism Reports</i> , 2020, 25, 100667.	1.1	9
23	Lessons from the Established Status Epilepticus Treatment Trial. <i>Epilepsy and Behavior</i> , 2019, 101, 106296.	1.7	8
24	Underdosing of Benzodiazepines in Patients With Status Epilepticus Enrolled in Established Status Epilepticus Treatment Trial. <i>Academic Emergency Medicine</i> , 2019, 26, 940-943.	1.8	39
25	Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 796-805.	2.5	8
26	Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. <i>New England Journal of Medicine</i> , 2019, 381, 2103-2113.	27.0	342
27	Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 158-167.	2.0	109
28	Conversion of a soluble diazepam prodrug to supersaturated diazepam for rapid intranasal delivery: Kinetics and stability. <i>Journal of Controlled Release</i> , 2018, 289, 1-9.	9.9	6
29	Rescue therapies for seizure emergencies: New modes of administration. <i>Epilepsia</i> , 2018, 59, 207-215.	5.1	44
30	A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. <i>PM and R</i> , 2017, 9, 743-750.	1.6	14
31	Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy. <i>Frontiers in Veterinary Science</i> , 2016, 3, 107.	2.2	11
32	A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1058-1066.	2.4	11
33	A review of intranasal formulations for the treatment of seizure emergencies. <i>Journal of Controlled Release</i> , 2016, 237, 147-159.	9.9	117
34	Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbolic-Digit Modalities Test in Adult Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 714-722.	2.0	6
35	A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 1025-1039.	0.8	10
36	Chirally Pure Prodrugs and Their Converting Enzymes Lead to High Supersaturation and Rapid Transcellular Permeation of Benzodiazepines. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2365-2371.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. <i>Epilepsia</i> , 2015, 56, 915-923.	5.1	13
38	Canine status epilepticus treated with fosphenytoin: A proof of principle study. <i>Epilepsia</i> , 2015, 56, 882-887.	5.1	17
39	Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials. <i>Epilepsia</i> , 2015, 56, 906-914.	5.1	8
40	Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. <i>CNS Drugs</i> , 2015, 29, 1009-1022.	5.9	24
41	Mechanisms of Antioxidant Induction with High-Dose N-Acetylcysteine in Childhood Cerebral Adrenoleukodystrophy. <i>CNS Drugs</i> , 2015, 29, 1041-1047.	5.9	13
42	A Pilot Study Assessing Pharmacokinetics and Tolerability of Oral and Intravenous Baclofen in Healthy Adult Volunteers. <i>Journal of Child Neurology</i> , 2015, 30, 37-41.	1.4	23
43	Water-soluble benzodiazepine prodrug/enzyme combinations for intranasal rescue therapies. <i>Epilepsy and Behavior</i> , 2015, 49, 347-350.	1.7	11
44	Development of benzodiazepines for out-of-hospital management of seizure emergencies. <i>Neurology: Clinical Practice</i> , 2015, 5, 80-85.	1.6	20
45	USL255 extended-release topiramate: Dose-proportional pharmacokinetics and tolerability in healthy volunteers. <i>Epilepsia</i> , 2014, 55, 1069-1076.	5.1	15
46	Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 935-942.	2.4	8
47	Feasibility study of a caregiver seizure alert system in canine epilepsy. <i>Epilepsy Research</i> , 2013, 106, 456-460.	1.6	34
48	A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. <i>Epilepsy Research</i> , 2013, 105, 362-367.	1.6	60
49	Bioavailability of Intranasal vs. Rectal Diazepam. <i>Epilepsy Research</i> , 2013, 103, 254-261.	1.6	37
50	N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases. <i>Clinical Neuropharmacology</i> , 2013, 36, 103-106.	0.7	165
51	Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. <i>Epilepsia</i> , 2013, 54, 1099-1105.	5.1	31
52	Intravenous topiramate: Safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. <i>Epilepsia</i> , 2013, 54, 1106-1111.	5.1	24
53	The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 193-202.	4.7	22
54	Clinical tolerance and toxicity of intravenous baclofen: A pilot study in a canine model. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2011, 4, 89-98.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Canine status epilepticus: Proof of principle studies. <i>Epilepsia</i> , 2009, 50, 14-15.	5.1	73
56	Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. <i>Epilepsy Research</i> , 2009, 84, 120-126.	1.6	23
57	Pharmacologic Considerations in the Treatment of Repetitive or Prolonged Seizures. <i>Journal of Child Neurology</i> , 2007, 22, 47S-52S.	1.4	11
58	Relative Bioavailability, Metabolism and Tolerability of Rectally Administered Oxcarbazepine Suspension. <i>Clinical Drug Investigation</i> , 2007, 27, 243-250.	2.2	4
59	Relative bioavailability of topiramate administered rectally. <i>Epilepsy Research</i> , 2003, 54, 91-96.	1.6	16
60	A Single-Blind, Crossover Comparison of the Pharmacokinetics and Cognitive Effects of a New Diazepam Rectal Gel with Intravenous Diazepam. <i>Epilepsia</i> , 1998, 39, 520-526.	5.1	78
61	A Comparison of Rectal Diazepam Gel and Placebo for Acute Repetitive Seizures. <i>New England Journal of Medicine</i> , 1998, 338, 1869-1875.	27.0	262
62	Failure of Absorption of Gabapentin After Rectal Administration. <i>Epilepsia</i> , 1997, 38, 1242-1244.	5.1	28
63	Relative Bioavailability of Rectally Administered Carbamazepine Suspension in Humans. <i>Epilepsia</i> , 1985, 26, 429-433.	5.1	50